AU2014318014C1 - Alpha-tea salt forms: compositions and uses for treating disease - Google Patents

Alpha-tea salt forms: compositions and uses for treating disease Download PDF

Info

Publication number
AU2014318014C1
AU2014318014C1 AU2014318014A AU2014318014A AU2014318014C1 AU 2014318014 C1 AU2014318014 C1 AU 2014318014C1 AU 2014318014 A AU2014318014 A AU 2014318014A AU 2014318014 A AU2014318014 A AU 2014318014A AU 2014318014 C1 AU2014318014 C1 AU 2014318014C1
Authority
AU
Australia
Prior art keywords
compound
pct
cancer
hydrate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014318014A
Other languages
English (en)
Other versions
AU2014318014A1 (en
AU2014318014B2 (en
Inventor
Thomas Adkins
Emmanuel T. Akporiaye
Barbara KIDON
Michael O'neill
Hongqiao Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of AU2014318014A1 publication Critical patent/AU2014318014A1/en
Publication of AU2014318014B2 publication Critical patent/AU2014318014B2/en
Application granted granted Critical
Publication of AU2014318014C1 publication Critical patent/AU2014318014C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014318014A 2013-09-06 2014-09-05 Alpha-tea salt forms: compositions and uses for treating disease Active AU2014318014C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874823P 2013-09-06 2013-09-06
US61/874,823 2013-09-06
PCT/US2014/054354 WO2015035212A1 (en) 2013-09-06 2014-09-05 Alpha-tea salt forms: compositions and uses for treating disease

Publications (3)

Publication Number Publication Date
AU2014318014A1 AU2014318014A1 (en) 2016-03-17
AU2014318014B2 AU2014318014B2 (en) 2018-06-07
AU2014318014C1 true AU2014318014C1 (en) 2018-11-15

Family

ID=51570908

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014318014A Active AU2014318014C1 (en) 2013-09-06 2014-09-05 Alpha-tea salt forms: compositions and uses for treating disease

Country Status (9)

Country Link
US (2) US10370350B2 (enExample)
EP (1) EP3041831B1 (enExample)
JP (2) JP6675985B2 (enExample)
AU (1) AU2014318014C1 (enExample)
CA (1) CA2922375C (enExample)
DK (1) DK3041831T3 (enExample)
ES (1) ES2766324T3 (enExample)
PL (1) PL3041831T3 (enExample)
WO (1) WO2015035212A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922375C (en) 2013-09-06 2021-06-15 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
CN107050432B (zh) * 2017-02-28 2019-09-10 上海交通大学医学院 胃泌素在制备诊断和治疗乳腺癌药物中的应用
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
EP3646873A1 (en) * 2018-10-31 2020-05-06 Aprofol AG Folate salts
CN111635390A (zh) * 2020-06-30 2020-09-08 江南大学 一种低泡型α-生育酚表面活性剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2001058889A1 (en) * 2000-02-11 2001-08-16 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2003039461A2 (en) * 2001-11-05 2003-05-15 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4629734Y1 (enExample) 1968-04-23 1971-10-14
JP2634047B2 (ja) * 1985-10-15 1997-07-23 ザ リポソ−ム カンパニ−，インコ−ポレイテツド アルファトコフェロールをベースとした小胞体
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US6770672B1 (en) 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2003053407A1 (en) 2001-12-19 2003-07-03 Research Development Foundation Liposomal delivery of vitamin e based compounds
CA2922375C (en) 2013-09-06 2021-06-15 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2001058889A1 (en) * 2000-02-11 2001-08-16 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
WO2003039461A2 (en) * 2001-11-05 2003-05-15 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, XIU-FANG ET AL, "Vitamin E analogues as anticancer agents: lessons from studies with .alpha.-tocopheryl succinate", MOLECULAR NUTRITION & FOOD RESEARCH, (2006), vol. 50, no. 8, doi:10.1002/MNFR.200500267, pages 675 - 685 *

Also Published As

Publication number Publication date
US10934267B2 (en) 2021-03-02
JP6675985B2 (ja) 2020-04-08
CA2922375C (en) 2021-06-15
WO2015035212A1 (en) 2015-03-12
AU2014318014A1 (en) 2016-03-17
ES2766324T3 (es) 2020-06-12
JP2016532714A (ja) 2016-10-20
EP3041831A1 (en) 2016-07-13
US20200148661A1 (en) 2020-05-14
EP3041831B1 (en) 2019-10-23
CA2922375A1 (en) 2015-03-12
AU2014318014B2 (en) 2018-06-07
JP2020063294A (ja) 2020-04-23
US20160214954A1 (en) 2016-07-28
PL3041831T3 (pl) 2021-07-19
US10370350B2 (en) 2019-08-06
DK3041831T3 (da) 2020-01-27

Similar Documents

Publication Publication Date Title
US10934267B2 (en) Alpha-tea salt forms: compositions and uses for treating disease
EA018152B1 (ru) Кристаллическая форма дигидрохлорида метил ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((метоксикарбонил)амино)-3-метилбутаноил)-2-пирролидинил)-1н-имидазол-5-ил)-4-бифенилил)-1н-имидазол-2-ил)-1-пирролидинил)карбонил)-2-метилпропил)карбамата
US12472187B2 (en) Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
KR20200019226A (ko) 약학 조성물
EP3007696B1 (en) Novel allosteric inhibitors of proteasome and methods of use thereof
IL278015B2 (en) A process for preparing modulators of p300 and/or cbp
CN119110799A (zh) 作为erbb抑制剂的多晶型物
EP3416950A1 (en) Max binders as myc modulators and uses thereof
WO2017198194A1 (zh) 一种硼酸和硼酸酯类化合物及其应用
JP7309608B2 (ja) 抗がん活性を有するステロイドサポニン
AU2019318046A1 (en) Histone demethylase 5 inhibitors and uses thereof
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
WO2022166774A1 (zh) 3-羟基-5-孕烷-20-酮衍生物的晶型及其制备方法和用途
CN112876510A (zh) 一种磷酸酯类多环化合物及其药物组合物和用途
AU2016323777B2 (en) DNA binding agents with a minor groove binding tail
EP2809647B1 (en) Mglu 2/3 agonists
CN103951716B (zh) 豆腐果苷衍生物及其制备方法和用途
CN120757534A (zh) 喹唑林类化合物及其用途

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 AUG 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 08 AUG 2018

FGA Letters patent sealed or granted (standard patent)